• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American College of Cardiology (ACC) 2022 Annual Meeting

April 2 - 4, 2022

  1. FORXIGA (Dapagliflozin)
  2. BRILINTA (ticagrelor)
  3. Reveal-CKD
  4. General CVRM
  5. Early BioPharmaceuticals

HTML

Prevalence of structural echocardiographic abnormalities in patients with type 2 diabetes in primary care: insights from the take care of me programme in 4 emerging countries

HTML

FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58

HTML

A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs with Heart Failure: PROMPT-HF

HTML

Cardiovascular disease and type 2 diabetes: treatment satisfaction, quality of life and diabetes related symptoms when receiving sodium glucose cotransporter 2 inhibitor versus other noninsulin diabetes medications

HTML

Prevalence and characteristics of heart failure with preserved, mid-range, and reduced ejection fraction ejection fraction in Spain: a retrospective cohort study using BIGPAC database

HTML

ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

HTML

Total Cardiovascular and Limb Events with Ticagrelor and Clopidogrel in Patients with Symptomatic PAD in the EUCLID Trial

HTML

A multimodality system-of-care program for acute coronary syndrome Improves guideline-directed medical therapy, outpatient floow-up, 30-day readmissions and emergency department visits: The ACS Advocate Project

HTML

Clinical correlates of ischemic and bleeding risk in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: insights from ALETHEIA, a multi-country observational study

HTML

Ticagrelor does not mediate its early beneficial effects in ST-elevation myocardial infarction by improving coronary microvascular dysfunction – the TIMES double-blind randomised controlled trial

HTML

Ticagrelor monotherapy after pci across the spectrum of high-risk patients: a deep dive into the TWILIGHT trial

HTML

UNDIAGNOSED STAGE 3 CHRONIC KIDNEY DISEASE IN PATIENTS WITH A HISTORY OF HEART FAILURE: A REPORT FROM REVEAL-CKD

HTML

PATIENT ENGAGEMENT ON AN INTEGRATED DIGITAL HEALTH PLATFORM POST HOSPITALIZATION FOR HEART FAILURE: AN INTERIM ANALYSIS

HTML

VEGF-D genetic variants are significantly associated to plasma VEGF-D levels and predict mortality in patients with cardiovascular diseases

HTML

ETESIAN: a phase 2b study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice